October 23, 2018
1 min read

IDx, Topcon sign agreement about AI diagnostic system

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

IDx reached an exclusivity agreement with Topcon to sell its artificial intelligence-based diagnostic system with the Topcon NW400 robotic fundus camera.

The agreement grants exclusive rights to IDx in the United States as the only autonomous AI company permitted to sell its products with the Topcon NW400, a joint press release said. In turn, IDx will only use the NW400 camera with IDx-DR, the company’s autonomous AI diagnostic system that detects diabetic retinopathy in fundus images.

Michael D. Abramoff, MD, PhD, founder and CEO of IDx, pointed out the “ease of use” of the NW400 camera and its ability to capture high-quality retinal images.

The autonomous AI-based diagnostic system, the first to be cleared by the FDA, does not require a physician to interpret images or results. The clearance followed a clinical trial that showed the system produced a successful diagnosis in 96% of patients. The system used the Topcon NW400 camera in the trial, with novice operators receiving minimal training to capture high-quality images using the camera.

“Our partnership with IDx further solidifies our position as a pioneer in the eye care business,” Fumio Ohue, managing executive officer of Topcon, said in the release. “Our efforts to deliver better workflow solutions, imaging technology and AI tools to eye care providers will be complemented by our work with IDx to bring autonomous diagnostics to a growing population of people with diabetes.”